These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 19623023

  • 1. Contrast enhanced sonography shows superior microvascular renal allograft perfusion in patients switched from cyclosporine A to everolimus.
    Kihm LP, Hinkel UP, Michael K, Sommerer C, Seckinger J, Morath C, Zeier M, Schwenger V.
    Transplantation; 2009 Jul 27; 88(2):261-5. PubMed ID: 19623023
    [Abstract] [Full Text] [Related]

  • 2. Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients.
    Seckinger J, Sommerer C, Hinkel UP, Hoffmann O, Zeier M, Schwenger V.
    J Hypertens; 2008 Nov 27; 26(11):2213-9. PubMed ID: 18854763
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation.
    Gude E, Gullestad L, Arora S, Simonsen S, Hoel I, Hartmann A, Holdaas H, Fiane AE, Geiran OR, Andreassen AK.
    J Heart Lung Transplant; 2010 Jun 27; 29(6):641-7. PubMed ID: 20304681
    [Abstract] [Full Text] [Related]

  • 5. Acute effects of calcineurin inhibitors on kidney allograft microperfusion visualized by contrast-enhanced sonography.
    Kihm LP, Blume C, Seckinger J, Hankel V, Stoffler D, Morath C, Zeier M, Schwenger V.
    Transplantation; 2012 Jun 15; 93(11):1125-9. PubMed ID: 22470107
    [Abstract] [Full Text] [Related]

  • 6. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 15; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 7. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years.
    Legendre C, Brault Y, Morales JM, Oberbauer R, Altieri P, Riad H, Mahony J, Messina M, Pussell B, Martínez JG, Lelong M, Burke JT, Neylan JF, Rapamune Maintenance Regimen Study Group.
    Clin Transplant; 2007 Mar 15; 21(3):330-6. PubMed ID: 17488381
    [Abstract] [Full Text] [Related]

  • 8. Complete switch to everolimus in long-term kidney transplants: evolution of the renal function.
    Fernández A, Marcén R, Galeano C, Caldés S, Amezquita Y, Villafruela J, Pascual J, Burgos J, Rodríguez-Mendiola N, Ortuño J.
    Transplant Proc; 2009 Mar 15; 41(6):2345-7. PubMed ID: 19715915
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 11. Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A.
    Pape L, Ahlenstiel T, Ehrich JH, Offner G.
    Pediatr Transplant; 2007 May 27; 11(3):291-5. PubMed ID: 17430485
    [Abstract] [Full Text] [Related]

  • 12. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
    Krüger B, Fischereder M, Jauch KW, Graeb C, Hoffmann U, Böger CA, Banas B, Obed A, Schlitt HJ, Krämer BK.
    Transplant Proc; 2007 Mar 27; 39(2):518-21. PubMed ID: 17362772
    [Abstract] [Full Text] [Related]

  • 13. Cyclosporine versus everolimus: effects on the glomerulus.
    Baas MC, Kers J, Florquin S, de Fijter JW, van der Heide JJ, van den Bergh Weerman MA, ten Berge IJ, Bemelman FJ.
    Clin Transplant; 2013 Mar 27; 27(4):535-40. PubMed ID: 23795805
    [Abstract] [Full Text] [Related]

  • 14. mTOR inhibitors: do they help preserve renal function?
    Moro J, Almenar L, Martínez-Dolz L, Agüero J, Rueda J, Arnau MA, Izquierdo M, Cano O, Sánchez-Lázaro I, Salvador A.
    Transplant Proc; 2007 Sep 27; 39(7):2135-7. PubMed ID: 17889116
    [Abstract] [Full Text] [Related]

  • 15. [Slowing progression of chronic allograft nephropathy by conversion from cyclosporin A to tacrolimus].
    Peng LK, Xie XB, Peng FH, Wang Y, Jiang Y, Lan GB, Fang CH, Nie MH.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb 27; 32(1):59-62. PubMed ID: 17344588
    [Abstract] [Full Text] [Related]

  • 16. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ, de Maar EF, Press RR, van Kan HJ, ten Berge IJ, Homan van der Heide JJ, de Fijter HW.
    Transplantation; 2009 Aug 15; 88(3):421-8. PubMed ID: 19667948
    [Abstract] [Full Text] [Related]

  • 17. Preservation of renal function after heart transplantation: initial single-center experience with sirolimus.
    De Meester JM, Van Vlem B, Walravens M, Vanderheyden M, Verstreken S, Goethals M, Kerre N, Wellens F.
    Transplant Proc; 2005 May 15; 37(4):1835-8. PubMed ID: 15919481
    [Abstract] [Full Text] [Related]

  • 18. Protocol conversion from a calcineurin inhibitor based therapy to sirolimus.
    Oberbauer R.
    Transplantation; 2009 Apr 27; 87(8 Suppl):S7-10. PubMed ID: 19384186
    [Abstract] [Full Text] [Related]

  • 19. Everolimus plus dosage reduction of cyclosporine in cardiac transplant recipients with chronic kidney disease: a two-year follow-up study.
    Fuchs U, Zittermann A, Hakim-Meibodi K, Börgermann J, Schulz U, Gummert JF.
    Transplant Proc; 2011 Jun 27; 43(5):1839-46. PubMed ID: 21693287
    [Abstract] [Full Text] [Related]

  • 20. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.
    Tedesco-Silva H, Vitko S, Pascual J, Eris J, Magee JC, Whelchel J, Civati G, Campbell S, Alves-Filho G, Bourbigot B, Garcia VD, Leone J, Esmeraldo R, Rigotti P, Cambi V, Haas T, 2306 and 2307 study groups.
    Transpl Int; 2007 Jan 27; 20(1):27-36. PubMed ID: 17181650
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.